SXTP Relative Valuation
SXTP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SXTP is overvalued; if below, it's undervalued.
Historical Valuation
60 Degrees Pharmaceuticals Inc (SXTP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 2.65 is considered Overvalued compared with the five-year average of -0.88. The fair price of 60 Degrees Pharmaceuticals Inc (SXTP) is between 0.48 to 0.85 according to relative valuation methord. Compared to the current price of 0.98 USD , 60 Degrees Pharmaceuticals Inc is Overvalued By 15.8%.
Relative Value
Fair Zone
0.48-0.85
Current Price：0.98
15.8%
Overvalued
-0.59
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
60 Degrees Pharmaceuticals Inc. (SXTP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.57
EV/EBIT
60 Degrees Pharmaceuticals Inc. (SXTP) has a current EV/EBIT of -1.57. The 5-year average EV/EBIT is -2.15. The thresholds are as follows: Strongly Undervalued below -5.41, Undervalued between -5.41 and -3.78, Fairly Valued between -0.52 and -3.78, Overvalued between -0.52 and 1.11, and Strongly Overvalued above 1.11. The current Forward EV/EBIT of -1.57 falls within the Historic Trend Line -Fairly Valued range.
2.65
PS
60 Degrees Pharmaceuticals Inc. (SXTP) has a current PS of 2.65. The 5-year average PS is 4.85. The thresholds are as follows: Strongly Undervalued below -6.67, Undervalued between -6.67 and -0.91, Fairly Valued between 10.60 and -0.91, Overvalued between 10.60 and 16.36, and Strongly Overvalued above 16.36. The current Forward PS of 2.65 falls within the Historic Trend Line -Fairly Valued range.
-0.64
P/OCF
60 Degrees Pharmaceuticals Inc. (SXTP) has a current P/OCF of -0.64. The 5-year average P/OCF is -0.78. The thresholds are as follows: Strongly Undervalued below -2.17, Undervalued between -2.17 and -1.47, Fairly Valued between -0.08 and -1.47, Overvalued between -0.08 and 0.62, and Strongly Overvalued above 0.62. The current Forward P/OCF of -0.64 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
60 Degrees Pharmaceuticals Inc. (SXTP) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
60 Degrees Pharmaceuticals Inc (SXTP) has a current Price-to-Book (P/B) ratio of -0.78. Compared to its 3-year average P/B ratio of -0.61 , the current P/B ratio is approximately 28.05% higher. Relative to its 5-year average P/B ratio of -0.61, the current P/B ratio is about 28.05% higher. 60 Degrees Pharmaceuticals Inc (SXTP) has a Forward Free Cash Flow (FCF) yield of approximately -144.42%. Compared to its 3-year average FCF yield of -160.81%, the current FCF yield is approximately -10.19% lower. Relative to its 5-year average FCF yield of -160.81% , the current FCF yield is about -10.19% lower.
-0.78
P/B
Median3y
-0.61
Median5y
-0.61
-144.42
FCF Yield
Median3y
-160.81
Median5y
-160.81
Competitors Valuation Multiple
The average P/S ratio for SXTP's competitors is 0.00, providing a benchmark for relative valuation. 60 Degrees Pharmaceuticals Inc Corp (SXTP) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 75.42%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SXTP decreased by 84.80% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.07 to -0.20.
The secondary factor is the Revenue Growth, contributed 75.42%to the performance.
Overall, the performance of SXTP in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is 60 Degrees Pharmaceuticals Inc (SXTP) currently overvalued or undervalued?
What is 60 Degrees Pharmaceuticals Inc (SXTP) fair value?
How does SXTP's valuation metrics compare to the industry average?
What is the current P/B ratio for 60 Degrees Pharmaceuticals Inc (SXTP) as of Dec 05 2025?
What is the current FCF Yield for 60 Degrees Pharmaceuticals Inc (SXTP) as of Dec 05 2025?
What is the current Forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP) as of Dec 05 2025?